SCHEMBL5377698

SCHEMBL5377698

COCOc1cc(Br)cc(C=O)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 5/20 0.39
MAOB P27338 5/20 0.39
ALDH1A1 P00352 7/20 0.36
MAPK1 P28482 1/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
TDP1 Q9NUW8 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
CYP1A2 P05177 1/20 0.33
CYP2C19 P33261 1/20 0.33
CYP2A6 P11509 1/20 0.33
ERN1 O75460 1/20 0.33
FDPS P14324 1/20 0.33
HDAC3 O15379 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC10 Q969S8 1/20 0.33
HDAC11 Q96DB2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5572530 0.87 NPC1 (0.39) MAOAMAOBALDH1A1MAPK1NPC1
SCHEMBL1486859 0.87 NPC1 (0.39) MAOAMAOBALDH1A1MAPK1NPC1
SCHEMBL1347260 0.85 FDPS (0.39) MAOAMAOBALDH1A1MAPK1NPC1
SCHEMBL5373918 0.83 HDAC3 (0.30) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL31274883 0.82 LMNA (0.43) MAOAMAOBALDH1A1SMN1; SMN2CYP1A2
SCHEMBL31471620 0.82 CYP1A1 (0.47) ALDH1A1NPC1RAB9ATDP1CYP1A2
SCHEMBL25198968 0.81 SOD1 (0.36) MAOBALDH1A1CYP2C19HDAC3HDAC4
SCHEMBL309108 0.81 SOD1 (0.40) MAOBCYP2C19HDAC3HDAC4HDAC1
SCHEMBL235612 0.80 ALDH1A1 (0.48) ALDH1A1NPC1RAB9ATDP1CYP1A2
SCHEMBL30374532 0.80 ALDH1A1 (0.48) ALDH1A1NPC1RAB9ATDP1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100469769-C Benzyl-pyridazinons as reverse transcriptase inhibitors ROCHE PALO ALTO LLC (CH) 2009-03-18 CN disclosed
US-7189718-B2 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC (US) 2007-03-13 US disclosed
CN-1764649-A Benzyl-pyridazinones as reverse transcriptase inhibitors ROCHE PALO ALTO LLC (CH) 2006-04-26 CN disclosed
EP-1608629-A1 BENZYL-PYRIDAZINONS AS REVERSE TRANSCRIPTASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-12-28 EP disclosed
US-20040198736-A1 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC 2004-10-07 US disclosed
WO-2004085406-A1 BENZYL-PYRIDAZINONS AS REVERSE TRANSCRIPTASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2004-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198736-A1 Non-nucleoside reverse transcriptase inhibitors POLR1A, POLR2A, POLR2E MAOA 1565/4885MAOB 1002/4885ALDH1A1 321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.